Background. Among all in-breast tumor recurrences (IBTR) following breast-conserving therapy (BCT), some comprise metachronous new primaries (NPs) while others are true recurrences (TRs). Establishing this distinction remains a challenge. Methods. We studied 3932 women who underwent BCT for stage I-III breast cancer from 1998 to 2008. Of these, 115 (2.9%) had an IBTR. Excluding patients with inoperable/unresectable recurrences or simultaneous distant metastases, 81 patients with isolated IBTR comprised the study population. An IBTR was categorized as an NP rather than a TR if it included an in situ component. The log-rank test and Kaplan-Meier method were used to evaluate disease-free survival (DFS) and overall survival (OS), and univariate and multivariate analyses were performed using Cox proportional hazards regression models. Results. At a median of 64.5 months from IBTR diagnosis, 28 of 81 patients had DFS events. Five-year DFS was 43.1% in the TR group (p = 0.0001) versus 80.3% in the NP group, while 5-year OS was 59.7% in the TR group versus 91.7% among those with NPs (p = 0.0011). On univariate analysis, increasing tumor size, high grade, positive margins, lymphovascular invasion, node involvement, lack of axillary surgery, chemotherapy, radiation therapy, and IBTR type (TR vs. NP) were significantly associated with worse DFS. Controlling for tumor size and margin status, TRs remained significantly associated with lower DFS (hazard ratio 3.717, 95% confidence interval 1.607-8.595, p = 0.002). Conclusion. The presence of an in situ component is associated with prognosis among patients with IBTR following BCT and may be useful in differentiating TRs and NPs.
Isolated locoregional recurrence (LRR) following breast-conserving therapy (BCT) arises in a minority of patients with localized disease. [1] [2] [3] [4] [5] Advances in treatment and screening have yielded favorable outcomes for early localized breast cancer, with contemporary studies suggesting a recurrence risk below 5% in select populations. [6] [7] [8] [9] Despite these advances in treating primary disease, LRRs remain a clinical challenge, with 10-year distant metastasis-free survival (DMFS) estimates ranging between 36 and 65%, and 10-year overall survival (OS) estimated between 39 and 64.5%. 7, [10] [11] [12] While chest wall and regional nodal recurrences likely arise from the primary tumor, in-breast tumor recurrence (IBTR) after BCT may represent a true recurrence (TR) or metachronous new primary (NP). There is no universally accepted method of determining which recurrences stem from the primary tumor and which have arisen de novo.
Most studies base this determination on anatomic distance from the original primary, in addition to a host of other features such as change in histologic type, hormone receptor status, and nuclear grade. [13] [14] [15] [16] [17] [18] [19] [20] Studies that use these factors to differentiate TRs and NPs have shown variable differences in prognosis between these entities, and it remains unclear whether management should be driven by these classifiers.
An alternate method of classifying recurrences may be to consider the presence of an in situ component. 21, 22 Invasive breast tumors often develop from in situ lesions, such as ductal carcinoma in situ (DCIS), and, indeed, the majority of primary invasive ductal cancers have an accompanying intraductal component. [23] [24] [25] [26] Genetic and molecular studies have shown that invasive cancers and their accompanying intraductal components share underlying similarities, suggesting that the two are related in origin. [27] [28] [29] Given the progression from intraductal to invasive carcinoma, invasive recurrences presenting with an intraductal component are likely to have evolved de novo from previously existing DCIS or normal tissue rather than from cells of the primary invasive tumor that survived despite treatment. Likewise, recurrences with no intraductal component may be more likely to represent a TR of primary invasive cancer rather than an NP tumor. In this study, we sought to evaluate the prognostic significance of a classification system defined by the presence or absence of an in situ component adjacent to invasive IBTR of breast cancer.
PATIENTS AND METHODS

Study Population
Between 1998 and 2008, a total of 3932 consecutive female patients with stage I-III invasive breast cancer were treated with BCT [breast-conserving surgery (BCS) and radiation therapy] at our institution. Patient data were prospectively collected in a multidisciplinary computerized database. Patients were excluded if they received neoadjuvant chemotherapy, had inflammatory breast cancer, or were not assessed for estrogen receptor (ER), progesterone receptor (PR), or human epidermal growth factor receptor 2 (HER2-neu) status. Overall, 162 (4.1%) patients had an invasive LRR as the first site of failure, 115 (2.9%) of which were IBTRs. After exclusion of 18 patients with simultaneous distant metastases (within 2 months of recurrence diagnosis), 7 patients with follow-up of \ 2 months from diagnosis of recurrence, 2 patients with lack of pathology reports, and 7 patients who did not have breast surgery, 81 patients with isolated, invasive IBTR treated with surgery comprised the study population.
An Institutional Review Board waiver was received for this retrospective study.
Tumor Characteristics
Information on multifocality, lymphovascular invasion (LVI), size, and histology was gathered from pathological reports of biopsy and surgical specimens. All pathology slides were reviewed at a single institution. An IBTR was determined to be an NP if it had an in situ component (ductal or lobular carcinoma in situ) within or directly adjacent to the invasive tumor component, and a TR if the specimen was invasive only (Fig. 1) 31 Equivocal HER2 was grouped as negative for analysis.
Definition of Endpoints
The primary endpoint of this study was disease-free survival (DFS) after diagnosis of IBTR. DFS events included second LRR, distant recurrence, death attributable to any cause, and second primary non-breast invasive cancer, as defined by Hudis et al. 32 OS, DMFS, and second LRR-free survival (LRR-FS) were analyzed as secondary endpoints. LRR was defined as invasive recurrence in the ipsilateral breast, chest wall, and/or regional nodes.
Statistical Analysis
The Fisher's exact or v 2 tests and Welch's t test were used to compare categorical and continuous variables, respectively, for patient and tumor characteristics of patients who had NPs and TRs. The Kaplan-Meier method was used to calculate DFS, OS, DMFS, and second LRR-FS, and the log-rank test was used to compare survival curves. Univariate and multivariate analyses were performed using Cox regression analysis. All p-values were two-sided, with values \ 0.05 considered significant.
RESULTS
Patient and Treatment Characteristics
A total of 81 patients with IBTR after BCT were analyzed. At initial diagnosis of primary breast cancer, all patients received BCS and adjuvant whole-breast radiotherapy. Fifty-two percent of patients received hormonal therapy and 65% of patients received chemotherapy. In most patients, radiation therapy was delivered to the whole breast using tangential fields at a median dose of 46.8 Gy [interquartile range (IQR) 46.8-50. 4 Gy]. Sixty-five patients received a boost to the tumor bed at a median dose of 10.0 Gy (IQR 9.5-14.0 Gy). Three patients were treated with partial breast irradiation and six patients (7.4%) received regional nodal irradiation. There were no significant differences in primary tumor treatment characteristics between TRs and NPs.
Patient and IBTR treatment characteristics are summarized in Table 1 . The median age at IBTR diagnosis was 58 years (range 36-87), median follow-up from diagnosis of recurrence was 64.5 months (range 12.8-177.1), and the median time interval from definitive surgery of the primary tumor to diagnosis with IBTR was 53.9 months (range 7.3-161.1). There were no significant differences in age or time to recurrence between patients with TRs and those with NPs.
After IBTR, 73 (90%) patients were treated with mastectomy and 8 (10%) were treated with repeat BCS. Five (6%) of 81 patients had positive margins, with TR patients more likely to have positive margins than NP patients. Forty-four (54%) patients were treated with chemotherapy, 42 (52%) with hormonal therapy, 6 (7%) with re-irradiation (median 56 Gy; all external beam within 3-9 years of the first radiation course; no major re-irradiation toxicities were observed), and 5 of 11 HER2-positive patients were treated with trastuzumab. TRs were more likely to have been treated with partial mastectomy than NPs (p = 0.01). There were no other significant differences in treatment between TRs and NPs, although TRs trended towards being more often treated with hormone therapy and radiation therapy (Table 1) .
Recurrent and Primary Tumor Characteristics
Seventy-three (90%) tumors were found in the breast only, while eight patients (three TRs and five NPs) additionally had involvement of the axilla (Table 2) . TRs tended to be larger than NPs (median size 1.25 vs. 0.7 cm, p = 0.02), and there were no significant differences between TRs and NPs in grade, multifocality, LVI, node involvement, histologic type, or receptor subtype.
In comparing primary tumor characteristics, TRs and NPs exhibited similar grade, multifocality, histology, and subtype; however, TRs tended to be larger (median size 1.7 vs. 1.15 cm, p = 0.01) and more frequently had LVI (41% vs. 17%, p = 0.03). Four of 27 TR patients had positive margins in primary surgery, three of which were invasive tumor and one of which was DCIS. NPs were more likely to have margins positive with DCIS, with all 5 of 54 patients with positive margins being positive with DCIS rather than invasive tumor (p = 0.03).
Outcomes After In-Breast Tumor Recurrences
Twenty-eight of 81 patients had a DFS event, including 14 s LRRs, 8 distant metastases, 4 deaths, and 2 primary non-breast or contralateral breast cancers. The 5-year DFS was 43.1% [95% confidence interval (CI) 23.0-62.1] for patients with TRs versus 80.3% (95% CI 66.4-88.9) for patients with NPs (p = 0.0001) (Fig. 2) . Similarly, OS, DMFS, and second LRR-FS differed between the two sets of patients (Fig. 2) 
Multivariate Analysis
In order to adjust for potential confounders, multivariate analysis was performed. Tumor size and margin status were the only two variables that significantly differed between TRs and NPs, and had significant associations with DFS on univariate analysis. When these two variables were included with IBTR subtype (TR vs. NP) in multivariate analysis, IBTR subtype remained independently associated with DFS (HR 3.717, 95% CI 1.607-8.595, p = 0.002). Tumor size also remained independently associated with DFS (HR 2.083 per cm, 95% CI 1.303-3.330, p = 0.002). Margin status was not significantly associated on multivariate analysis despite its association on univariate analysis.
DISCUSSION
These results suggest that IBTRs after BCT have an improved DFS when an in situ component is associated with the invasive recurrence. When defined by the presence of adjacent in situ carcinoma, NP tumors in our cohort did not exhibit a longer time to 'recurrence', but were detected at smaller sizes. This may reflect a difference in the natural history of TRs and NPs, with NP tumors progressing from de novo or non-excised in situ carcinoma rather than from residual primary invasive cancer.
Most prior studies have differentiated NPs from TRs, with location as the main distinguishing criterion. [13] [14] [15] [16] [18] [19] [20] [21] [22] [33] [34] [35] Under this classification schema, NPs have been shown to arise sooner after primary surgery and generally have better prognosis than TRs in the tumor bed; 13, 15, 16, 19 however, there continues to be a need for further exploration of how best to identify and treat true TRs compared with NPs. For instance, among studies that consider location of IBTR, it is unclear how far a tumor must be from the tumor bed to be considered an NP. 14, 15, 19 The likelihood of an NP developing near the tumor bed is also significant, especially in considering that most breast cancers arise in the upper outer quadrant. 36 Furthermore, when not combined with other classification criteria such as change in histologic type, location alone may not portend a statistically significant difference in prognosis. 14, 37 In our study, we explored an alternative method to distinguish NPs versus TRs-by the presence of an adjacent in situ component. Using this criterion, new NPs had significantly better outcomes than TRs, with a 5-year DFS of 43 and 80% for TRs and NPs, respectively. This difference in DFS outcome is similar to or greater than values reported in other studies, with 10-year distant DFS values reported between 26 and 56% for TRs, and 77 and 94% for NPs. The difference in OS seen in our study is also similar to that reported in other classification schemes; 5-year OS was 60 and 92% for TRs and NPs, respectively, while prior studies have reported 10-year OS ranging from 46 to 76% for TRs, and 64 to 92% for NPs. 13, 15, 16, 19, 21 When classifying NPs by the presence of an in situ component in our cohort, NPs tended to be smaller than 21 In addition to shorter time to recurrence, we also expected TRs to more commonly have the same histology as the primary tumor. All six tumors that changed histologic type were classified as NPs in our study.
These results must be interpreted in the context of the study design. A small number of patients underwent repeat BCT, an approach that was more frequently performed in TRs than NPs and has since been reported as a feasible alternative to salvage mastectomy, although with limited long-term data. 38, 39 We further found that receipt of chemotherapy and radiation therapy was associated with a decline in DFS, likely due to confounding by indication. Differences in treatment, among other tumor characteristics, may impact the association of NPs with favorable outcome, although multivariate analysis was used to control for this possibility. We included tumor size and margin status in this analysis due to their significant associations with DFS and significant differences between TRs and NPs, but other variables may also play a role in determining outcome. Finally, our study is limited by a lack of molecular assays that may best determine which 'recurrences' truly share molecular identity with their primary lesions.
40,41
CONCLUSIONS
When defined by the presence of an in situ component, NPs have favorable outcomes when compared with TRs.
Consideration of an in situ component at the time of IBTR may add prognostic value to the assessment of subsequent risk when used in combination with location, histologic type, and receptor status. This characteristic may be particularly informative among patients whose primary tumor characteristics are unknown. Further validation is needed to validate these findings and better inform local and systemic management of IBTR. IBTR in-breast tumor recurrence, LVI lymphovascular invasion, LN lymph node, BCS breast-conserving surgery, SLNB sentinel lymph node biopsy, DFS disease-free survival, HR hazard ratio, CI confidence interval, HER human epidermal growth factor receptor
